▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Onc.AI Awarded FDA Breakthrough Device Designation for Serial CT Response Score Deep Learning Model

Onc.AI, a digital health company developing AI-driven oncology clinical management solutions using Deep Learning imaging AI, today announced that the U.S. Food and Drug Administration (FDA) has awarde...

Business Wire

Breakthrough Serial CTRS Model Also Has Potential to Transform Oncology Drug Development

SAN CARLOS, Calif. & WATERLOO, Ontario: Onc.AI, a digital health company developing AI-driven oncology clinical management solutions using Deep Learning imaging AI, today announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Device Designation for its “Serial CTRS” (Serial CT Response Score) AI model. Serial CTRS is an artificial intelligence (AI)-based prognostic tool that uses deep learning to analyze CT scans and stratify patients into high- or low-mortality risk categories. This designation underscores the potential of Onc.AI’s pipeline of category-leading imaging AI models to provide an early and automated risk prognosis, enabling clinicians to optimize treatment decisions and surveillance of patients with metastatic non-small cell lung cancer.

Recently, Onc.AI presented results at the Society for Immunotherapy of Cancer (SITC), showcasing a multi-institutional study demonstrating that Serial CTRS improved the prediction of overall survival for patients receiving immunotherapy compared to traditional imaging assessment tools. This highlights the model’s ability to deliver more accurate, data-driven insights into patient outcomes, enabling more precise, personalized cancer care.

“We are honored to be awarded Breakthrough Device Designation for our Serial CTRS AI model,” said Akshay Nanduri, CEO of Onc.AI. “Onc.AI aims to equip oncologists with vital, automated prognostic insights using routinely collected diagnostic imaging scans and ultimately improve treatment strategy and provide risk stratification throughout a cancer patient’s journey.”

“As longstanding partners of Onc.AI, we are thrilled to see the application of Flatiron’s high-quality, curated real-world data in the development and validation of regulatory-grade AI models for clinical use,” said Jacqueline Law, VP of Corporate Strategy at Flatiron Health. “We look forward to supporting Onc.AI’s efforts collaborating with the FDA and achieving additional milestones together.”

Building on its ability to deliver robust insights for patient management, Serial CTRS also holds promise for transforming oncology drug development programs. Notably, it has demonstrated outperformance of the standard RECIST 1.1 in predicting overall survival, paving the way for superior decision-making in trial design and clinical development decisions for novel oncology therapeutics.

“As part of our ongoing data and clinical collaboration with Onc.AI, we are excited to be evaluating Serial CTRS. Having been involved in product definition and evaluating results throughout the evolution of this product, I look forward to seeing this breakthrough technology enter the clinic and impact early phase trials and clinical development,” said Dwight Owen, MD, MS, Associate Professor of Medicine and Head of Thoracic Oncology at The James Cancer Center at OSU.

About Onc.AI

Onc.AI is a digital health company developing AI-driven oncology clinical management solutions using advanced Deep Learning applied to routine diagnostic images. The company’s platform is applied at the point of care to medical oncologists and is also leveraged by global pharmaceutical leaders to accelerate oncology drug development. Onc.AI is backed by premier institutional investors, including: Sandbox/Blue Venture Fund, Action Potential Venture Capital, MassMutual Alternative Investments, Accomplice, Digitalis, KdT, and Life Extension Ventures. Onc.AI is also supported by the National Cancer Institute SBIR program (1R44CA291456-01A1).

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Alibaba Group Announces March Quarter 2025 and Fiscal Year 2025 Results

$BABA #alibaba--Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), “Alibaba”, “Alibaba Group” or the “company”)…

Red Hat Optimizes Red Hat AI to Speed Enterprise AI Deployments Across…

Red Hat, the world's leading provider of open source solutions, today continues to deliver customer choice in enterprise AI with the introduction of Red…

U.S. Data Center Construction Market Outlook Report 2025-2030 Featuring…

The "U.S. Data Center Construction Market - Industry Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The…

J.D. Power Names Joshua Peirez New CEO

J.D. Power today announced that Joshua Peirez will assume the role of President and CEO of J.D. Power, guiding the company in its next phase of growth…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!